Adding targeted therapy to chemotherapy in Phase III trial is safe, results in 66% complete remission rate A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid […]
Courtney DiNardo
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML)
Findings suggest AML treatments may be tailored to individual molecular profiles HOUSTON – A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) […]
